A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT06966700Phase 3Recruiting
- Lead sponsor
- Merck Sharp & Dohme LLC (Industry)
- Enrollment
- 2,400 (estimated)
- Start date
- 30 Jun 2025
- Primary completion
- 23 Mar 2033 (estimated)
- Study completion
- 29 Dec 2034
- Last update posted
- 13 Oct 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- None
- Arms
- 2
Interventions
- Sacituzumab tirumotecan Biological
- Pembrolizumab Biological
- Rescue Medication Drug
- Carboplatin Drug
- Paclitaxel Drug
- Doxorubicin Drug
- Epirubicin Drug
- Cyclophosphamide Drug
- Capecitabine Drug
- Olaparib Drug
Conditions and primary outcome
- Breast Neoplasms
- Triple Negative Breast Neoplasms
- HR Low-Positive/HER2-Negative Breast Neoplasms
Primary outcome
Percentage of Participants with Pathological Complete Response (pCR) at the Time of Definitive Surgery (Up to approximately 30 weeks); Event-Free Survival (EFS) (Up to approximately 92 months)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
1 on PubMedTroFuse-032 study design: pembrolizumab plus sacituzumab tirumotecan or chemotherapy followed by pembrolizumab plus chemotherapy as neoadjuvant therapy for early-stage, triple-negative breast cancer or HR-low+/HER2- breast cancer.
Future oncology (London, England) · 2026 Oct 14
PubMed 42872715 (opens in a new tab)DOI 10.1080/14796694.2026.2732590 (opens in a new tab)
Citations from PubMed, U.S. National Library of Medicine; abstracts are not stored. A publication lists this study’s NCT number and may be a review that cites many studies.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT06966700 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.